The nonstructural protein 10（nsp10） of porcine reproductive and respiratory syndrome virus（PRRSV） encodes for helicase which plays a vital role in viral replication. In the present study, a truncated form of nsp10...The nonstructural protein 10（nsp10） of porcine reproductive and respiratory syndrome virus（PRRSV） encodes for helicase which plays a vital role in viral replication. In the present study, a truncated form of nsp10, termed nsp10 a, was found in PRRSV-infected cells and the production of nsp10 a was strain-specific. Mass spectrometric analysis and deletion mutagenesis indicated that nsp10 a may be short of about 70 amino acids in the N terminus of nsp10. Further studies by rescuing recombinant viruses showed that the Glu-69 in nsp10 was the key amino acid for nsp10 a production. Finally, we demonstrated that nsp10 a exerted little influence on the growth kinetics of PRRSV in vitro.展开更多
Hepatitis C virus(HCV)infection remains a major public health concern,with 56.8 million people chronically infected worldwide and 1.5 million new infections yearly.1 As a leading cause of liver-related mortality,chron...Hepatitis C virus(HCV)infection remains a major public health concern,with 56.8 million people chronically infected worldwide and 1.5 million new infections yearly.1 As a leading cause of liver-related mortality,chronic HCV infection is associated with 19%of hepatocellular carcinoma and 21%of cirrhosis cases.2 The advent of direct-acting antiviral agents(DAA)in recent decades,which target viral replication proteins and inhibit various steps in the HCV life cycle,has shown remarkable progress in achieving a cure for hepatitis C.DAA regimens block replication complex formation,reduce virion assembly and release,accelerate viral RNA degradation,and are associated with the restoration of liver function and improvement in histology.Pangenotypic DAA regimens,with DAA combinations targeting different and complementary stages of the HCV cycle,have been recommended by current practice guidelines3 and can be initiated without knowledge of the HCV genotype and subtype.As the global prevalence of chronic HCV infections has decreased by seven million since 2015,the World Health Organization has set the goals of a 90%reduction in new infections,an 80%reduction in diagnosed patients,and a 65%reduction in HCV-related mortality by 2030.To accomplish this,expanded access,active HCV screening,and linkage to care are required.展开更多
基金supported by the National Key Technology R&D Program of China (2015BAD12B01-2)the Major Program of National Natural Science Foundation of China (31490603)the earmarked fund for Modern Agroindustry Technology Research System of China (CARS-36)
文摘The nonstructural protein 10（nsp10） of porcine reproductive and respiratory syndrome virus（PRRSV） encodes for helicase which plays a vital role in viral replication. In the present study, a truncated form of nsp10, termed nsp10 a, was found in PRRSV-infected cells and the production of nsp10 a was strain-specific. Mass spectrometric analysis and deletion mutagenesis indicated that nsp10 a may be short of about 70 amino acids in the N terminus of nsp10. Further studies by rescuing recombinant viruses showed that the Glu-69 in nsp10 was the key amino acid for nsp10 a production. Finally, we demonstrated that nsp10 a exerted little influence on the growth kinetics of PRRSV in vitro.
基金supported by the National Natural Science Foundation of China(Nos.91129705,81070340,81971921)the Shanghai Pujiang Talent Program(09PJ1402600)the Shanghai Science and Technology Innovation Action Plan(24142202800).
文摘Hepatitis C virus(HCV)infection remains a major public health concern,with 56.8 million people chronically infected worldwide and 1.5 million new infections yearly.1 As a leading cause of liver-related mortality,chronic HCV infection is associated with 19%of hepatocellular carcinoma and 21%of cirrhosis cases.2 The advent of direct-acting antiviral agents(DAA)in recent decades,which target viral replication proteins and inhibit various steps in the HCV life cycle,has shown remarkable progress in achieving a cure for hepatitis C.DAA regimens block replication complex formation,reduce virion assembly and release,accelerate viral RNA degradation,and are associated with the restoration of liver function and improvement in histology.Pangenotypic DAA regimens,with DAA combinations targeting different and complementary stages of the HCV cycle,have been recommended by current practice guidelines3 and can be initiated without knowledge of the HCV genotype and subtype.As the global prevalence of chronic HCV infections has decreased by seven million since 2015,the World Health Organization has set the goals of a 90%reduction in new infections,an 80%reduction in diagnosed patients,and a 65%reduction in HCV-related mortality by 2030.To accomplish this,expanded access,active HCV screening,and linkage to care are required.
